CSPC Pharmaceutical Group Limited (CSPCY)
OTCMKTS · Delayed Price · Currency is USD
4.970
-0.040 (-0.80%)
Feb 6, 2026, 9:30 AM EST
CSPC Pharmaceutical Group Revenue
CSPC Pharmaceutical Group had revenue of 6.62B CNY in the quarter ending September 30, 2025, with 3.37% growth. This brings the company's revenue in the last twelve months to 26.21B, down -13.40% year-over-year. In the year 2024, CSPC Pharmaceutical Group had annual revenue of 29.01B, down -7.76%.
Revenue (ttm)
26.21B CNY
Revenue Growth
-13.40%
P/S Ratio
3.89
Revenue / Employee
1.36M CNY
Employees
19,266
Market Cap
14.31B USD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 29.01B | -2.44B | -7.76% |
| Dec 31, 2023 | 31.45B | 513.21M | 1.66% |
| Dec 31, 2022 | 30.94B | 3.07B | 11.02% |
| Dec 31, 2021 | 27.87B | 2.92B | 11.73% |
| Dec 31, 2020 | 24.94B | 2.84B | 12.84% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 588.02M |
| Glass House Brands | 196.17M |
| Vaxart | 148.20M |
| Elite Pharmaceuticals | 122.89M |
| Silence Therapeutics | 25.83M |
| OpGen | 9.00M |
| Stem Cell Authority | 3.33M |
CSPC Pharmaceutical Group News
- 10 days ago - AstraZeneca strikes up to $18.5B obesity drug deal with China’s CSPC Pharmaceutical - Seeking Alpha
- 10 days ago - AstraZeneca Strikes Multibillion-Dollar Obesity Deal With China's CSPC - WSJ
- 10 days ago - China's CSPC Pharmaceutical, AstraZeneca partner on long-acting obesity drugs - Seeking Alpha
- 10 days ago - China's CSPC Pharmaceutical inks deal with AstraZeneca for weight loss therapy - Reuters
- 6 months ago - Madrigal in-pact with CSPC Pharma for obesity drug license - Seeking Alpha
- 8 months ago - Medtide Launches Hong Kong IPO to Boost Weight-loss Business - Benzinga
- 8 months ago - AstraZeneca Inks China AI Research Deal For Chronic Diseases - NDTV
- 8 months ago - AstraZeneca Inks Research Pact With China's CSPC Pharmaceuticals Focused On AI-Driven Research, Valued Up To $5.33 Billion - Benzinga